Literature DB >> 28375033

The Role of IFN-alpha in Experimental and Clinical Uveitis.

Xiaoli Liu1, Maria Diedrichs-Möhring1, Gerhild Wildner1.   

Abstract

PURPOSE: IFN-α is the only treatment capable of inducing long-term remission in some patients with ocular Behçet's disease. In this review, we focus on immune mechanisms of IFN-α in animal models and patients and compare the outcome of different clinical studies.
METHODS: Review of literature using PubMed and Google and original data from rat models with monophasic/chronic or relapsing experimental autoimmune uveitis treated with IFN-α.
RESULTS: The role of IFN-α and its effect on various cell types were investigated, in some cases with contradictory results. Some patients respond very well to IFN-α treatment, while others are non-responders, which was reflected in the uveitis rat models: relapsing uveitis was ameliorated, the monophasic/chronic disease even aggravated.
CONCLUSIONS: Despite intensive investigations in patients and animal models, the immune mechanisms explaining the therapeutic effect of IFN-α in ocular Behçet's disease are not yet fully understood and need further investigation.

Entities:  

Keywords:  NK cells; Th1; Th17; rat experimental autoimmune uveitis; regulatory T cells

Mesh:

Substances:

Year:  2017        PMID: 28375033     DOI: 10.1080/09273948.2017.1298822

Source DB:  PubMed          Journal:  Ocul Immunol Inflamm        ISSN: 0927-3948            Impact factor:   3.070


  3 in total

Review 1.  Host-Directed Antiviral Therapy.

Authors:  Naveen Kumar; Shalini Sharma; Ram Kumar; Bhupendra N Tripathi; Sanjay Barua; Hinh Ly; Barry T Rouse
Journal:  Clin Microbiol Rev       Date:  2020-05-13       Impact factor: 26.132

2.  PD-1 Targeted Nanoparticles Inhibit Activated T Cells and Alleviate Autoimmunity via Suppression of Cellular Energy Metabolism Mediated by PKM2.

Authors:  Zhangluxi Liu; Jing Xu; Hongxi Li; Jia Shu; Guannan Su; Chunjiang Zhou; Peizeng Yang
Journal:  Int J Nanomedicine       Date:  2022-04-13

Review 3.  Insights Into Type I and III Interferons in Asthma and Exacerbations.

Authors:  Helen E Rich; Danielle Antos; Natalie R Melton; John F Alcorn; Michelle L Manni
Journal:  Front Immunol       Date:  2020-09-25       Impact factor: 7.561

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.